Vaxcyte启动Opus-3三期临床试验,为首批曾接种低效价肺炎疫苗的成人受试者接种Vax-31

美股速递
Feb 12

生物制药公司Vaxcyte, Inc.(纳斯达克代码:PCVX)宣布,其针对成人肺炎链球菌疫苗的Opus-3三期临床试验已取得重要进展,首批曾接种过低效价肺炎疫苗的参与者已成功接种候选疫苗Vax-31。这项关键性研究旨在评估Vax-31在该特定人群中的免疫原性及安全性表现。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10